Navigation Links
Watson Third Quarter 2011 Net Revenue Climbs 23% to $1.1 Billion; Non-GAAP Diluted EPS of $1.09; GAAP Diluted EPS of $0.54
Date:11/1/2011

ted future results or other non-historical facts are forward-looking statements that reflect Watson's current perspective of existing trends and information as of the date of this release.  For instance, any statements in this press release concerning prospects related to Watson's strategic initiatives, product introductions and anticipated financial performance are forward-looking statements.  It is important to note that Watson's goals and expectations are not predictions of actual performance.  Watson's performance, at times, will differ from its goals and expectations.  Actual results may differ materially from Watson's current expectations depending upon a number of factors affecting Watson's business.  These factors include, among others, the inherent uncertainty associated with financial projections; the impact of competitive products and pricing; timely and successful consummation of strategic transactions;  the difficulty of predicting the timing or outcome of litigation and risks that an adverse outcome in such litigation could render Watson liable for substantial financial damages; successful integration of strategic transactions including the acquisition of Specifar Pharmaceuticals; the ability to recognize the anticipated synergies and benefits of strategic transactions; variability of revenue mix between the Company's Brand, Generic and Distribution business units; periodic dependence on a small number of products for a material source of net revenue or income; variability of trade buying patterns; fluctuations in foreign currency exchange rates; changes in generally accepted accounting principles; risks that the carrying values of assets may be negatively impacted by future events and circumstances; the timing and success of product launches; the difficulty of predicting the timing or outcome of product development efforts and FDA or other regulatory agency approvals or actions; the uncertainty associated with the identif
'/>"/>
SOURCE Watson Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related medicine technology :

1. Watson Confirms Court Grants Preliminary Injunction Preventing Launch of Generic LOVENOX®
2. Watson to Present at the 2011 Annual Credit Suisse Health Care Conference
3. Watson Confirms Daytrana(R) Patent Challenge
4. Watson Provides Update on District Court Order Concerning Generic Version of LOVENOX®
5. Watson Confirms District Court Order Concerning Generic Version of LOVENOX(R)
6. Watson Confirms EMBEDA(R) Patent Challenge
7. Watson Launches Generic FEMCON(R) Fe
8. Watson to Host Conference Call and Webcast to Discuss Third Quarter 2011 Earnings
9. Watson to Present at the Jefferies 2011 Global Healthcare Conference
10. Watson Confirms Amphastar Patent Lawsuit
11. Watson Pharmaceuticals Announces Approval of Amphastars Generic LOVENOX(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2015)... , April 17, 2015  AbbVie Inc. ("AbbVie") (NYSE ... that it has extended the expiration of its exchange offer ... of Pharmacyclics, Inc. to 5 p.m., New York ... On April 17, 2015, AbbVie also voluntarily withdrew its ... Act in order to provide the FTC with additional time ...
(Date:4/17/2015)... Research and Markets ( http://www.researchandmarkets.com/research/6tdwh8/medical_device ... "Medical Device Outsourcing - Global Strategic Business Report" ... report analyzes the worldwide markets for Medical Device ... Categories: Class I, Class II, and Class III. ... Include - Radiology, Orthopedic, Neurology, Cardiology, and Others. ...
(Date:4/17/2015)... , April 17, 2015 ASSESS ... mutation   is a viable alternative to tumour biopsy   ... in all patients with advanced NSCLC   AstraZeneca ... of plasma circulating tumour DNA (ctDNA) testing for epidermal growth ... advanced non-small cell lung cancer (NSCLC) in clinical practice. [ ...
Breaking Medicine Technology:AbbVie Extends Exchange Offer to Acquire Pharmacyclics, Inc. 2AbbVie Extends Exchange Offer to Acquire Pharmacyclics, Inc. 3AbbVie Extends Exchange Offer to Acquire Pharmacyclics, Inc. 4Medical Device Outsourcing (Radiology, Orthopedic, Neurology, Cardiology, and Others) Market 2015 - Global Strategic Business Report 2Medical Device Outsourcing (Radiology, Orthopedic, Neurology, Cardiology, and Others) Market 2015 - Global Strategic Business Report 3"Real World" Data Support Use of Blood Test for EGFR Mutation in Advanced NSCLC 2"Real World" Data Support Use of Blood Test for EGFR Mutation in Advanced NSCLC 3"Real World" Data Support Use of Blood Test for EGFR Mutation in Advanced NSCLC 4
... 2007 - Ceragenix Pharmaceuticals,Inc. (OTCBB:CGXP), a biopharmaceutical ... announced that a catheter,treated with a Ceragenin ... 21 day study., In the study, polyurethane ... a phosphate-suffered solution along with an,untreated catheter. ...
... PGL; NASDAQ: PGLA) is pleased to announce that its ... late breaking news,presentation by the European Association for the ... the results of this liver,cancer trial at the American ... ,In expectation of having final data fully analysed and ...
Cached Medicine Technology:Ceragenix Announces Ceragenins Virtually Prevent Catheter Biofilm,Formation in 21 Day Study 2Ceragenix Announces Ceragenins Virtually Prevent Catheter Biofilm,Formation in 21 Day Study 3PI-88 Data to be Presented at Key International Conferences 2PI-88 Data to be Presented at Key International Conferences 3
(Date:4/18/2015)... Carinsurancesavings.biz has released a new blog ... cheaper during Spring. , Spring can be a ... should make sure they compare the newest policies before ... learn more about Spring car insurance offers by reading ... quotes are becoming more and more popular. Many insurance ...
(Date:4/18/2015)... 2015 "I wanted to live ... a healthful juice that contained essential vitamins, minerals ... "It increases my energy, improves skin elasticity and ... developed Tapp's Juice to contain fruits, vegetables and ... physical and mental fatigue. It features a great ...
(Date:4/18/2015)... 2015 Lowcostcarinsuranceprice.com has released a new ... on auto insurance prices . , Drivers ... vehicle theft may have to pay more for auto ... insurance policies can also offer protection against vehicle theft. ... compared online on a single website: http://lowcostcarinsuranceprice.com/ ...
(Date:4/18/2015)... 18, 2015 Thousand of DePuy Pinnacle ... of individuals who were allegedly harmed by a metal-on-metal ... forward in the U.S. District Court, Northern District of ... Court has amended an earlier Case Management Order to ... things, the new amendment permits the claims of up ...
(Date:4/18/2015)... 2015 On April 14th, 2015, Symantec released ... which they say, “exposes a tactical shift by cyberattackers.” With ... were introduced in 2014 - almost a million a day ... to be identified and patched by prominent manufacturers – as ... doing business in a digital world can be fraught with ...
Breaking Medicine News(10 mins):Health News:Auto Insurance Plans Are Cheaper During Spring! 2Health News:High Rates Of Car Theft Can Have An Impact on Auto Insurance Prices! 2Health News:DePuy Pinnacle Hip Lawsuits: Federal Litigation Amends Case Management Order to Allow for Joinder of Unrelated Claims 2Health News:DePuy Pinnacle Hip Lawsuits: Federal Litigation Amends Case Management Order to Allow for Joinder of Unrelated Claims 3Health News:Cyber Attackers Continue to Fine Tune Deception and Stealth Tactics According to New Report 2Health News:Cyber Attackers Continue to Fine Tune Deception and Stealth Tactics According to New Report 3Health News:Cyber Attackers Continue to Fine Tune Deception and Stealth Tactics According to New Report 4Health News:Cyber Attackers Continue to Fine Tune Deception and Stealth Tactics According to New Report 5
... Sheriff Adrian Garcia will deliver the keynote address, "The Harris ... 9 a.m., Friday (March 2) at the University of Houston ... attend the keynote address. A question-and-answer period will follow. ... Houston Area Social Work Awards Breakfast hosted by the UH ...
... A new method for creating nanofibers made of proteins, ... University (NYU-Poly), promises to greatly improve drug delivery methods ... disease, as well as aid in the regeneration of ... differently, this same development could point the way to ...
... release is available in French . ... CHUM Hospital,s International Health, will be joining the World Health ... funding of the fight against Noma. This disease, scientifically called ... Sub-Saharan Africa. Despite the existence of a cheap and easy ...
... By Steven Reinberg HealthDay Reporter , ... bring their children to the emergency room with fevers ... "Self-referred febrile [feverish] children should not be generalized, and ... ill patients," said lead researcher Dr. Yvette van Ierland, ...
... Exposure to bisphenol A (BPA), a controversial chemical commonly used ... disease later in life, a new study suggests. ... drinks, but also may be exposed through drinking water, dental ... researchers compared BPA levels in 758 people who were initially ...
... TAMPA, Fla. -- Researchers at Moffitt Cancer Center ... that the XL888 inhibitor can prevent resistance to the ... melanoma. Vemurafenib resistance is characterized by a diminished ... researchers, the balance between apoptosis and cell survival is ...
Cached Medicine News:Health News:Sheriff Adrian Garcia delivers keynote at social work awards breakfast 2Health News:Nanofiber breakthrough holds promise for medicine and microprocessors 2Health News:Montrealer heads to Congo to fight childhood disfigurement 2Health News:Parents Often Right to Bring Kids With Fever to the ER: Study 2Health News:Parents Often Right to Bring Kids With Fever to the ER: Study 3Health News:BPA Exposure May Raise Risk of Heart Disease 2Health News:Researchers find potential solution to melanoma's resistance to vemurafenib 2
... CoaguChek System has been providing accurate, reliable PT/INR ... point of care. , The CoaguChek System is ... self-testing when monitoring on Coumadin (warfarin sodium) therapy. ... a result from a fingerstick drop (10ul) of ...
The QuickScreen Pro Multi Drug Screening Test is a rapid, self-timing, qualitative immunoassay for,the detection of drugs of abuse in urine....
... The ADC drugs of abuse tests are ... at the SAMHSA recommended cut-off as confirmed by ... result. A more specific alternative method (such as ... a confirmed result. Professional judgment should be applied ...
The Osteomark NTx Point of Care (POC)device allows physicians to monitor their patients response to anti-resorptive drugs as early as 3-6 months from starting treatment. Osteomark NTx shows you and y...
Medicine Products: